{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:17:48Z","timestamp":1790705868023,"version":"4.1.0"},"reference-count":23,"publisher":"American Diabetes Association","issue":"2","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,2,1]]},"abstract":"<jats:p>The clinical presentation of type 1 diabetes usually involves symptoms such as polyuria and polydipsia. However, investigators in the Diabetes Prevention Trial of Type 1 Diabetes (DPT-1) have detected a group of subjects with type 1 diabetes who have a different phenotype. These subjects are asymptomatic, have normal (&amp;lt;6.1 mmol\/l) (group A) or impaired (6.1- &amp;lt;7.0 mmol\/l) (group B)fasting glucose, but have 2-h glucose values &amp;gt;11.1 mmol\/l on their oral glucose tolerance tests (OGTT). Of the 585 OGTTs performed on islet cell antibody (ICA)-positive relatives with insulin autoantibodies (IAA) or low first-phase insulin response (FPIR), normal glucose tolerance (NGT) was found in 427 subjects; impaired glucose tolerance (IGT) was found in 87 subjects,and diabetes was found by 2-h OGTT criteria alone in 61 subjects. Despite marked differences in 2-h glucose values (NGT 5.8 \u00b1 1.1 mmol\/l, IGT 8.9\u00b1 0.9 mmol\/l, and group A 13.5 \u00b1 2.5 mmol\/l), there were no significant differences in fasting glucose values among NGT (4.8 \u00b1 0.5 mmol\/l), IGT (5.03 \u00b1 0.5 mmol\/l), and group A (4.99 \u00b1 0.7 mmol\/l) categories. Mean FPIR was higher in subjects with NGT compared with subjects with IGT and subjects diagnosed by 2-h OGTT criteria alone. However,the correlation between FPIR and 2-h glucose value was low(r2 = 0.14). Multivariate analysis demonstrated that additional independent variables provide smaller contributions to the 2-h glucose value. In conclusion, there are asymptomatic type 1 diabetic subjects whose diabetes was diagnosed by the 2-h criteria on OGTT alone. Despite the importance of \u03b2-cell dysfunction in the pathogenesis of type 1 diabetes,factors other than impaired FPIR must also contribute to postprandial glucose tolerance in these subjects.<\/jats:p>","DOI":"10.2337\/diabetes.50.2.470","type":"journal-article","created":{"date-parts":[[2007,3,6]],"date-time":"2007-03-06T19:04:22Z","timestamp":1173207862000},"page":"470-476","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":55,"title":["Type 1 Diabetes Manifested Solely by 2-h Oral Glucose Tolerance Test Criteria"],"prefix":"10.2337","volume":"50","author":[{"given":"Carla J.","family":"Greenbaum","sequence":"first","affiliation":[{"name":"From the Department of Veterans Affairs (C.J.G.), Puget Sound Health Care System and the Department of Medicine (C.J.G.), University of Washington,Seattle, Washington; and the H. Lee Moffitt Cancer Center and Research Institute (D.C., J.P.K.), University of South Florida, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cuthbertson","sequence":"additional","affiliation":[{"name":"From the Department of Veterans Affairs (C.J.G.), Puget Sound Health Care System and the Department of Medicine (C.J.G.), University of Washington,Seattle, Washington; and the H. Lee Moffitt Cancer Center and Research Institute (D.C., J.P.K.), University of South Florida, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey P.","family":"Krischer","sequence":"additional","affiliation":[{"name":"From the Department of Veterans Affairs (C.J.G.), Puget Sound Health Care System and the Department of Medicine (C.J.G.), University of Washington,Seattle, Washington; and the H. Lee Moffitt Cancer Center and Research Institute (D.C., J.P.K.), University of South Florida, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Diabetes Prevention Trial of Type 1 Diabetes Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031208245581200_REF1","unstructured":"DPT-1 Study Group: The Diabetes Prevention Trial of Type 1 Diabetes(Abstract). Diabetes\u200843 (Suppl. 1) 159A, 1994"},{"key":"2022031208245581200_REF2","unstructured":"DPT-1 Study Group: The Diabetes Prevention Trial of Type 1 Diabetes: implementation of screening and staging of relatives (Abstract). Diabetes\u200844 (Suppl. 1):129A, 1995."},{"key":"2022031208245581200_REF3","doi-asserted-by":"crossref","unstructured":"Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care\u200820: 1183-1197,1997","DOI":"10.2337\/diacare.20.7.1183"},{"key":"2022031208245581200_REF4","doi-asserted-by":"crossref","unstructured":"Yu L, Rewers M, Gianani R, Kawasaki E, Zhang Y, Verge C, Chase P,Klingensmith G, Erlich H, Norris J, Eisenbarth GS: Antiislet autoantibodies usually develop sequentially rather than simultaneously. J Clin Endocrinol Metab\u200881:4264-4267, 1996","DOI":"10.1210\/jcem.81.12.8954025"},{"key":"2022031208245581200_REF5","doi-asserted-by":"crossref","unstructured":"Bingley PJ, ICARUS Group: Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives: the ICARUS data set. Diabetes\u200845:1720-1728, 1996","DOI":"10.2337\/diab.45.12.1720"},{"key":"2022031208245581200_REF6","doi-asserted-by":"crossref","unstructured":"McCulloch D, Bingley P, Colman P, Jackson R, Gale E, ICARUS Group:Comparison of bolus and infusion protocols for determining acute insulin response to intravenous glucose in normal humans. Diabetes Care\u200816: 911-915,1993","DOI":"10.2337\/diacare.16.6.911"},{"key":"2022031208245581200_REF7","doi-asserted-by":"crossref","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia\u200828:412-419, 1985","DOI":"10.1007\/BF00280883"},{"key":"2022031208245581200_REF8","doi-asserted-by":"crossref","unstructured":"Byrne M, Sturis J, Sobel R, Polonsky K: Elevated plasma glucose 2 h postchallenge predicts defects in \u03b2-cell function. Am J Physiol\u200833:E572-E579, 1996","DOI":"10.1152\/ajpendo.1996.270.4.E572"},{"key":"2022031208245581200_REF9","doi-asserted-by":"crossref","unstructured":"Carlsson A, Sundkvist G, Groop L, Tuomi T:l Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab\u200885:76-80, 2000","DOI":"10.1210\/jc.85.1.76"},{"key":"2022031208245581200_REF10","doi-asserted-by":"crossref","unstructured":"Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A,Nisse\u0301n M,Ehrnstro\u0308m BO,Forse\u0301n B, Snickars B, Lahti K, Forsblom C,Saloranta C, Taskinen MR, Groop LC: Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes\u200848:150-157, 1999","DOI":"10.2337\/diabetes.48.1.150"},{"key":"2022031208245581200_REF11","doi-asserted-by":"crossref","unstructured":"Zimmet PZ, Elliott RB, Mackay IR, Tuomi T, Rowley MJ, Pilcher CC,Knowles WJ: Autoantibodies to glutamic acid decarboxylase and insulin in islet cell antibody positive presymptomatic type 1 diabetes mellitus: frequency and segregation by age and gender. Diabet Med\u200811: 866-871,1994","DOI":"10.1111\/j.1464-5491.1994.tb00370.x"},{"key":"2022031208245581200_REF12","doi-asserted-by":"crossref","unstructured":"Burkeholder JN, Pickens JM, Womack WN: Oral glucose tolerance test in siblings of children with diabetes mellitus. Diabetes\u200816:156-160, 1967","DOI":"10.2337\/diab.16.3.156"},{"key":"2022031208245581200_REF13","doi-asserted-by":"crossref","unstructured":"Fajans SS, Cloutier MC, Crowther RL: Banting lecture: clinical and etiological heterogeneity of idiopathic diabetes mellitus. Diabetes\u200827:1112-1125, 1978","DOI":"10.2337\/diab.27.11.1112"},{"key":"2022031208245581200_REF14","doi-asserted-by":"crossref","unstructured":"Fajans SS: Heterogeneity within type II and MODY diabetes. In Comparison of Type 1 and Type II Diabetes: Advances in Experimental Medicine and Biology. Vranic M, Hollenberg CH, Steiner G, Eds. New York, Plenum Publishing, 1985, p.65-87","DOI":"10.1007\/978-1-4757-1850-8_5"},{"key":"2022031208245581200_REF15","doi-asserted-by":"crossref","unstructured":"Reaven GM, Olefsky JM: Relationship between heterogeneity of insulin responses and insulin resistance in normal subjects and patients with chemical diabetes. Diabetologia\u200813: 201-206,1977","DOI":"10.1007\/BF01219700"},{"key":"2022031208245581200_REF16","doi-asserted-by":"crossref","unstructured":"Rosenbloom AL: Insulin responses of children with chemical diabetes mellitus. N Engl J Med\u2008282:1228-1232, 1970","DOI":"10.1056\/NEJM197005282822203"},{"key":"2022031208245581200_REF17","doi-asserted-by":"crossref","unstructured":"Rosenbloom AL, Wheeler L, Bianchi R, Chin FT, Tiwary CM, Grgic A:Ageadjusted analysis of insulin responses during normal and abnormal glucose tolerance tests in children and adolescents. Diabetes\u200824: 820-828,1975","DOI":"10.2337\/diab.24.9.820"},{"key":"2022031208245581200_REF18","doi-asserted-by":"crossref","unstructured":"Rosenbloom AL, Hunt SS, Rosenbloom EK, Maclaren NK: Ten-year prognosis of impaired glucose tolerance in siblings of patients with insulin-dependent diabetes. Diabetes\u200831: 385-387,1982","DOI":"10.2337\/diabetes.31.5.385"},{"key":"2022031208245581200_REF19","doi-asserted-by":"crossref","unstructured":"National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes\u200828:1039-1057, 1979","DOI":"10.2337\/diab.28.12.1039"},{"key":"2022031208245581200_REF20","doi-asserted-by":"crossref","unstructured":"McCance DR, Hanson RL, Charles MA, Jacobsson LTH, Pettitt DJ,Bennett PH, Knowler WC: Comparison of tests of glycated hemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ\u2008308:1323-1328, 1994","DOI":"10.1136\/bmj.308.6940.1323"},{"key":"2022031208245581200_REF21","doi-asserted-by":"crossref","unstructured":"Charles MA, Balkau B, Vauzelle-Kervoeden F, Thibult N, Eschwege E:Revision of diagnostic criteria for diabetes. Lancet\u2008348: 1657-1658,1996","DOI":"10.1016\/S0140-6736(05)65719-4"},{"key":"2022031208245581200_REF22","doi-asserted-by":"crossref","unstructured":"Engelgau MM, Thompson TJ, Herman WH, Boyle JP, Aubert RE, Kenny SJ,Badran A, Sous ES, Ali MA: Comparison of fasting and 2-h glucose and HbA1c levels for diagnosing diabetes: diagnostic criteria and performance revisited. Diabetes Care\u200820: 785-791,1997","DOI":"10.2337\/diacare.20.5.785"},{"key":"2022031208245581200_REF23","doi-asserted-by":"crossref","unstructured":"Lipton RB, Atchison J, Dorman JS, Duquesnoy RJ, Eckenrode K,Orchard TJ, LaPorte RE, Riley WJ, Kuller LH, Drash AL, Becker DJ: Genetic,immunological, and metabolic determinants of risk for type 1 diabetes mellitus in families. Diabet Med\u20089:224-232, 1992","DOI":"10.1111\/j.1464-5491.1992.tb01766.x"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/50\/2\/470\/646726\/0500470.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/50\/2\/470\/646726\/0500470.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:09:25Z","timestamp":1667405365000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/50\/2\/470\/13392\/Type-1-Diabetes-Manifested-Solely-by-2-h-Oral"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,2,1]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,2,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diabetes.50.2.470","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,2,1]]}}}